-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell Therapeutics Announces Data From Phase 2 Trial Evaluating Participants Surpassing Expected Benchmarks For Metastatic Breast Cancer

Benzinga·01/27/2026 12:37:08
Listen to the news

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces new positive Phase 2 survival data highlighting multiple patients surpassing expected benchmarks for metastatic breast cancer and survival length over 18 months in 9 cases as of their last assessment.